Methods for evaluating novel biomarkers - a new paradigm.
about
Relationship between inflammatory cytokines and uric acid levels with adverse cardiovascular outcomes in patients with stable coronary heart disease.Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I.Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetesPlasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29)Smoking-Associated DNA Methylation Biomarkers and Their Predictive Value for All-Cause and Cardiovascular MortalityRisk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor.New directions in cardiovascular risk assessment: the role of secondary risk stratification markers.Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke.Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission.Evaluation of the use of the fourth version FloTrac system in cardiac output measurement before and after cardiopulmonary bypass.Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus.Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction.The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
P2860
Q34430337-F6A3B5DF-8A2C-4051-85EF-962E98170E16Q35662925-1380A463-7748-4B8A-B3F1-645C10634406Q35841197-9A24368F-FD7D-4FDB-8ABC-DC7C7E801F03Q36334718-243D13C1-6095-4C0B-9645-C3A1A9B13DB4Q36456169-9F7A416F-8FD0-480E-8F20-5126473A57E0Q36633993-94DF06F1-836C-47F2-86AD-392E5ED21F8DQ38018722-87873489-1C8B-4962-A22C-7F476FB62E1EQ41357862-98B35089-C231-47DB-A93D-A0491B7B1FF7Q45825276-5073BC5E-56E4-430E-A12B-63F411AA8C6DQ48177268-F8378057-568D-48A8-BD39-0E691ABA2384Q51351331-67605B27-02C5-4208-A1A0-819E7C95B4E8Q51503137-5C5B80C3-46B5-40EC-B2C8-F9ACEEEEF509Q53093013-80EA3D18-CC6F-4C7B-8567-3730F06D7BA8
P2860
Methods for evaluating novel biomarkers - a new paradigm.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Methods for evaluating novel biomarkers - a new paradigm.
@ast
Methods for evaluating novel biomarkers - a new paradigm.
@en
Methods for evaluating novel biomarkers - a new paradigm.
@nl
type
label
Methods for evaluating novel biomarkers - a new paradigm.
@ast
Methods for evaluating novel biomarkers - a new paradigm.
@en
Methods for evaluating novel biomarkers - a new paradigm.
@nl
prefLabel
Methods for evaluating novel biomarkers - a new paradigm.
@ast
Methods for evaluating novel biomarkers - a new paradigm.
@en
Methods for evaluating novel biomarkers - a new paradigm.
@nl
P2860
P1476
Methods for evaluating novel biomarkers - a new paradigm.
@en
P2093
P2860
P304
P356
10.1111/J.1742-1241.2010.02469.X
P577
2010-12-01T00:00:00Z